Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632146 | 0.81 | KIF11 (0.44) | KIF11 | |
| SCHEMBL9716225 | 0.79 | MEN1 (0.48) | GPR84 | |
| SCHEMBL133385 | 0.78 | S1PR1 (0.60) | KIF11S1PR1 | |
| SCHEMBL29689517 | 0.78 | GPR84 (0.47) | KIF11GPR84S1PR1 | |
| SCHEMBL909285 | 0.78 | GPR84 (0.47) | KIF11GPR84S1PR1 | |
| SCHEMBL1585710 | 0.78 | L3MBTL1 (0.50) | GPR84 | |
| SCHEMBL10845214 | 0.75 | NOTUM (0.50) | KIF11 | |
| SCHEMBL163728 | 0.73 | KIF11 (1.00) | KIF11BACE1GLO1AGXT | |
| SCHEMBL29914837 | 0.72 | KIF11 (0.78) | KIF11 | |
| SCHEMBL197238 | 0.72 | KIF11 (0.78) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1387829-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002090333-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | CBR1, CBR3, CHRM1 | KIF11 4153/4885BACE1 3166/4885GPR84 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.